Age, gender and efflux transporter activity influence imatinib efficacy in chronic myeloid leukemia patients

Saved in:
Bibliographic Details
Published inLeukemia research Vol. 82; pp. 33 - 35
Main Authors Vasconcelos, Flavia C., Bonecker, Simone T., de Souza, Paloma S., Scheiner, Marcos Antonio Mauricio, Amaral, Natalia, Zalcberg, Ilana, Thuler, Luiz Claudio S., Maia, Raquel C.
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.07.2019
Subjects
Adult
Age Factors
Antineoplastic Agents - metabolism
Antineoplastic Agents - therapeutic use
ATP Binding Cassette Transporter, Subfamily B, Member 1 - genetics
ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism
B-Lymphocytes - drug effects
B-Lymphocytes - metabolism
B-Lymphocytes - pathology
Biological Transport
Biomarkers, Tumor - genetics
Biomarkers, Tumor - metabolism
Female
Humans
Imatinib Mesylate - metabolism
Imatinib Mesylate - therapeutic use
K562 Cells
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology
Male
Middle Aged
Primary Cell Culture
Progesterone - pharmacology
Proto-Oncogene Proteins c-abl - genetics
Proto-Oncogene Proteins c-abl - metabolism
Sex Factors
Treatment Outcome
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Other Sources-1
ObjectType-Article-2
content type line 63
ObjectType-Correspondence-1
ISSN:0145-2126
1873-5835
DOI:10.1016/j.leukres.2019.05.012